Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Krill Oil 350 mg Ingredients & Drug Interactions

by Spring Valley

Softgel Capsule Category: Fat/fatty Acid
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Krill Oil 350 mg is a dietary supplement by Spring Valley with 1 active ingredient. Its ingredients are commonly taken for heart and cholesterol support, high triglycerides, joint pain and inflammation.Based on those ingredients, 976 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Krill Oil. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Krill Oil 350 mg by Spring Valley

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 4 of its 4 active ingredients.
  • “Krill Oil” is listed as a grouped ingredient — the label gives one combined amount (350 mg) without saying how much of each component you get.
  • “Omega-3 Fatty Acids” is listed as a grouped ingredient — the label gives one combined amount (90 mg) without saying how much of each component you get.

Spring Valley Krill Oil contains 4 active ingredients: krill oil itself (a marine source of omega-3 fatty acids), plus omega-3 fatty acids, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), phospholipids, and astaxanthin, a naturally occurring pigment from krill. The product comes in a gelatin capsule as the inactive ingredient.

Does it work?

Insufficient evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Insufficient

There isn't enough reliable clinical evidence to rate this product's ingredients for its stated purpose.

Why this rating?
  • The label markets this product for: Heart health.
  • We looked for evidence on: Cardiovascular disease (CVD), Coronary heart disease (CHD), Heart failure, Hypertension, Hypertriglyceridemia, Hyperlipidemia — and 3 related terms.
  • The closest evidence on file: Astaxanthin is rated "Insufficient Reliable Evidence To Rate" for Heart failure (Natural Medicines).
  • Also on file: Astaxanthin is rated "Insufficient Reliable Evidence To Rate" for Hyperlipidemia, Hypertension.

The effectiveness data we hold covers astaxanthin only. For age-related cognitive decline, age-related macular degeneration (AMD), aging skin, Alzheimer disease, athletic performance, and carpal tunnel syndrome, the evidence is insufficient to rate astaxanthin's effectiveness.

We don't have effectiveness ratings on file for the other components of this krill oil product.

The evidence, ingredient by ingredient Krill Oil Docosahexaenoic Acid (dha) Astaxanthin

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Astaxanthin is generally well tolerated in studies, though long-term safety data are limited. The most common side effects reported are abdominal pain, diarrhea, and red-colored stools.

In clinical trials, a small number of participants at higher doses experienced increased bowel movements or severe stomach pain. The safety data advises against astaxanthin during pregnancy and breastfeeding because there isn't enough information to know whether it's safe for either.

Side effects, ingredient by ingredient Krill Oil Docosahexaenoic Acid (dha) Astaxanthin

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 1 matched ingredient can interact with medications — Astaxanthin.
  • The most serious interaction on file is rated Moderate.
  • For scale: 672 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check with your doctor or pharmacist if you take any drugs metabolized by the liver enzyme CYP3A4—including certain statins, some blood pressure medications, and immunosuppressants—or by CYP2B6. Astaxanthin may theoretically lower their blood levels.

We could not check eicosapentaenoic acid, docosahexaenoic acid, or phospholipids for drug interactions; if you take prescription medications, discuss this product with your own healthcare provider to be sure.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with insufficient evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Krill oil supplements appeal to people looking for omega-3 fatty acids, but this one contains astaxanthin, which may affect how your liver processes certain medications. If you take statins, blood pressure drugs, immunosuppressants, or other medications your liver metabolizes, talk with your doctor or pharmacist before starting.

Women who are pregnant or breastfeeding should discuss this product with their healthcare provider first.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 1 of 4 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Nov 21, 2020.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Krill Oil 350 mg, straight from the product label.

Brand Spring Valley
Net contents 60 Small Softgel(s)
Market status On market
Date entered into DSLD Nov 21, 2020
DSLD ID 239797
Product type Fat/fatty Acid
Supplement form Softgel Capsule
Dietary claims / uses Nutrient, All Other, Qualified Health, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Krill Oil 350 mg by Spring Valley, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Softgel(s)
Maximum serving Sizes:
1 Softgel(s)
IngredientAmount% DV
Krill Oil350 mg--
Omega-3 Fatty Acids90 mg--
Eicosapentaenoic Acid50 mg--
Docosahexaenoic Acid24 mg--
Phospholipids130 mg--
Cholesterol5 mg2%
Astaxanthin17 mcg--

Other ingredients: Gelatin Capsule

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Seals/Symbols

MSC-C-52297 Certified Sustainable Seafood MSC www.msc.org From an MSC certified sustainable fishery.

Brand IP Statement(s)

Superba2 is a trademark of the Aker Group.

Superba2 Patented Improved

FDA Disclaimer Statement

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Formulation

Superior 100% Pure 3X more pure than regular Krill Oil

Heart health

No fishy aftertaste or odor

Product of antarctic ocean, encapsulated and bottled in the United States.

Supportive, but not conclusive research shows that consumption of EPA and DHA Omega-3 fatty acids may reduce the risk of coronary heart disease.

No gluten

Salts and other impurities are removed from Suberba2 krill oil via a patented process to provide the purest krill oil available.

Formula

Krill Oil 350 mg per softgel 90 mg Omega-3

Krill Oil is a source of Omega-3 fatty acids and may reduce the risk of coronary heart disease.

350 mg is the minimum fill per softgel. Due to the natural variability of krill oil, each softgel may include more than 350 mg to ensure label potency.

With phospholipids for easy absorption Unlike fish oils, krill oil carries Omega-3s in the form of phospholipids that deliver the fatty acids to your body's cells. Standard fish oils lack this phospholipid complex.

FDA Statement of Identity

Dietary Supplement

Suggested/Recommended/Usage/Directions

1 per day

Suggested Use: As a dietary supplement, take one (1) softgel daily, preferably with a meal.

Precautions

Contains crustacean shellfish (krill).

Warning: If you are pregnant, nursing, taking any medications or have any medical condition, consult your doctor before use. Supplementation with Omega-3 fatty acids should be avoided in patients with inherited or acquired bleeding predispositions, including those taking anticoagulants.

Discontinue use and consult your doctor if any adverse reactions occur. As with any product containing Omega-3 fatty acids, adhere carefully to the amount recommended by your doctor.

Keep out of reach of children.

For your protection, do not use if imprinted seal under cap is broken or missing.

Storage

For optimal storage conditions, store in a cool, dry place with the cap tightly closed. Avoid excessive heat or freezing.

General Statements

Discard seals, empty & replace cap Plastic bottle how2recycle.info

See for yourself

Krill Oil 350 mg by Spring Valley label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Krill Oil 350 mg by Spring Valley

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size1 Softgel(s) Dosage formSoftgel Capsule Amounts shown are per serving.

Krill Oil

Interacts with
208 drugs
350 mg per serving

Krill oil is a source of omega-3 fatty acids (EPA and DHA) bound to phospholipids, which may help absorption. It is most studied for lowering triglyce...

Krill Oil monograph & interactions

Other (inactive) ingredients: Gelatin Capsule. These complete the product’s ingredient list but are not active constituents.

Interaction report

Krill Oil 350 mg by Spring Valley Drug Interactions

Want to check YOUR meds against Krill Oil 350 mg?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
976Drugs
976 Moderate

Ingredients driving the most interactions

Krill Oil 208

Each ingredient & the kinds of drugs it affects

For each ingredient in Krill Oil 350 mg with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Krill Oil2 drug types · 208 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, krill oil may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.
Taking high doses of omega-3 fatty acids from fish oil can modestly decrease platelet aggregation. Since krill oil also contains these fatty acids, taking high doses of krill oil might also inhibit platelet aggregation. Theoretically, taking high doses of krill oil with antiplatelet or anticoagulant drugs might increase the risk of bleeding. However, the omega-3 content of krill oil is much lower than that of fish oil.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, taking krill oil with antidiabetes drugs might increase the risk of hypoglycemia.
Some research in animals and humans shows that krill oil might lower blood glucose levels. However, a small study shows that taking krill oil does not reduce blood glucose levels in patients with type 2 diabetes, most of whom were taking antidiabetes drugs.

Likelihood Possible Evidence B
The maker

Brand information

Manufacturer and brand details for Krill Oil 350 mg, from the product label.

Spring Valley

See all Spring Valley products
Name
Wal-Mart Stores, Inc.
City
Bentonville
State
AR
ZipCode
72716
Phone Number
1-866-251-1662
Web Address
Walmart.com/springvalley
Pharmacist Counseling Corner

Krill Oil 350 mg by Spring Valley: Common Questions

Does Krill Oil 350 mg by Spring Valley interact with any medications?
Yes. Based on its ingredients, Krill Oil 350 mg has a known interaction with 976 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Krill Oil 350 mg contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
What is astaxanthin and why is it in krill oil?
Astaxanthin is a natural red pigment found in krill and other marine organisms. It's included in this supplement as an antioxidant component, though we don't have strong evidence that it works for the conditions it's marketed for.
Can I take this if I'm pregnant or breastfeeding?
The safety data advises against it. There isn't enough information on astaxanthin in pregnancy and breastfeeding, so it's best to avoid this product during both periods. Talk with your doctor or pharmacist for personalized advice.
What side effects might I experience?
Most people tolerate it well, but the most common side effects are abdominal pain, diarrhea, and red-colored stools. At higher doses, some people have had more bowel movements or severe stomach pain. Stop and check with your pharmacist if side effects concern you.
Does this supplement actually work for age-related macular degeneration or cognitive decline?
We don't have reliable evidence to say whether astaxanthin works for these or other conditions this product is marketed for. The data we hold rates the evidence as insufficient.
Are there any fillers or added ingredients I should know about?
The product contains a gelatin capsule as an inactive ingredient. If you're vegetarian or vegan, this matters—gelatin is animal-derived.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Krill Oil 350 mg is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Krill Oil 350 mg label
Sources

Sources & How We Checked

Krill Oil 350 mg's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 65 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Krill Oil 13 references
  1. Leaf A. On the reanalysis of the GISSI-Prevenzione. Circulation 2002;105:1874-5. PubMed
  2. Connor WE. n-3 Fatty acids from fish and fish oil: panacea or nostrum? Am J Clin Nutr 2001;74;415-6. PubMed
  3. Calder PC. N-3 polyunsaturated fatty acids, inflammation and immunity: pouring oil on troubled waters or another fishy tale? Nutr Res 2001;21:309-41. DOI
  4. Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev 2004;9:420-8.
  5. Sampalis F, Bunea R, Pelland MF, et al. Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea. Altern Med Rev 2003;8:171-9.
  6. Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12-24. PubMed
  7. Tandy S, Chung RW, Wat E, et al. Dietary krill oil supplementation reduces hepatic steatosis, glycemia, and hypercholesterolemia in high-fat-fed mice. J Agric Food Chem 10-14-2009;57:9339-45. PubMed
  8. Maki, K. C., Reeves, M. S., Farmer, M., Griinari, M., Berge, K., Vik, H., Hubacher, R., and Rains, T. M. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr.R PubMed
  9. Albert BB, Derraik JG, Brennan CM, et al. Supplementation with a blend of krill and salmon oil is associated with increased metabolic risk in overweight men. Am J Clin Nutr 2015;102(1):49-57.
  10. Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. Nutr Res 2014;34(2):126-33. PubMed
  11. Lobraico JM, DiLello LC, Butler AD, Cordisco ME, Petrini JR, Ahmadi R. Effects of krill oil on endothelial function and other cardiovascular risk factors in participants with type 2 diabetes, a randomized controlled trial. BMJ Open Diabetes Res Care. 2015 PubMed
  12. van der Wurff ISM, von Schacky C, Bergeland T, Zeegers MP, Kirschner PA, de Groot RHM. Krill oil supplementation's effect on school grades in typically developing adolescents. Prostaglandins Leukot Essent Fatty Acids 2023;191:102553. PubMed
  13. van der Wurff ISM, von Schacky C, Bergeland T, et al. Effect of 1 year krill oil supplementation on cognitive achievement of Dutch adolescents: A double-blind randomized controlled trial. Nutrients. 2019;11(6):1230. PubMed

See these in context on the Krill Oil monograph →

Docosahexaenoic Acid (dha) 49 references
  1. Akedo I, Ishikawa H, Nakamura T, et al. Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules (abstract). Jpn J Clin Oncol PubMed
  2. Prisco D, Paniccia R, Bandinelli B, et al. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 1998;1:105-12.
  3. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997;66:649-59.
  4. Toft I, Bonaa KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. Ann Intern Med 1995;123:911-8.
  5. Sacks FM, Hebert P, Appel LJ, et al. Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the trials of hypertension prevention. J Hypertens 1994;12:209-13.
  6. Vandongen R, Mori TA, Burke V, et al. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. Hypertension 1993;22:371-9. PubMed
  7. FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-Rpt0272-38-Appendix-D-Reference
  8. Pedersen HS, Mulvad G, Seidelin KN, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet 1999;353:812-3. PubMed
  9. Ito Y, Suzuki K, Imai H, et al. Effects of polyunsaturated fatty acids on atrophic gastritis in a Japanese population. Cancer Lett 2001;163:171-8. PubMed
  10. Kris-Ehterton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57. PubMed
  11. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002;76:1007-15.. PubMed
  12. Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160:996-8.. PubMed
  13. Leng GC, Smith FB, Fowkes FG, et al. Relationship between plasma essential fatty acids and smoking, serum lipids, blood pressure and haemostatic and rheological factors. Prostaglandins Leukot Essent Fatty Acids 1994;51:101-8. PubMed
  14. Nelson GJ, Schmidt PS, Bartolini GL, et al. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 1997;32:1129-36. PubMed
  15. Wheaton DH, Hoffman DR, Locke KG, et al. Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. Arch Ophthalmol 2003;121:1269-78. PubMed
  16. Malcolm CA, McCulloch DL, Montgomery C, et al. Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: a double blind, prospective, randomised trial. Arch Dis Child Fetal Neonatal Ed 2003;88: DOI
  17. Sanjurjo P, Ruiz-Sanz JI, Jimeno P, et al. Supplementation with docosahexaenoic acid in the last trimester of pregnancy: maternal-fetal biochemical findings. J Perinat Med 2004;32:132-6.
  18. Montgomery C, Speake BK, Cameron A, et al. Maternal docosahexaenoic acid supplementation and fetal accretion. Br J Nutr 2003;90:135-45. DOI
  19. Lauritzen L, Hoppe C, Straarup EM, Michaelsen KF. Maternal fish oil supplementation in lactation and growth during the first 2.5 years of life. Pediatr Res 2005;58:235-42. PubMed
  20. Hawkes JS, Bryan DL, Makrides M, et al. A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha. Am J Clin Nutr 2002;75:75
  21. Uauy R, Hoffman DR, Mena P, et al. Term infant studies of DHA and ARA supplementation on neurodevelopment: Results of randomized controlled trials. J Pediatr 2003;143:S17-25. PubMed
  22. Decsi, T., Campoy, C., and Koletzko, B. Effect of N-3 polyunsaturated fatty acid supplementation in pregnancy: the Nuheal trial. Adv.Exp Med Biol 2005;569:109-113. PubMed
  23. Mori, T. A., Bao, D. Q., Burke, V., Puddey, I. B., and Beilin, L. J. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999;34(2):253-260. PubMed
  24. Otto, S. J., van Houwelingen, A. C., and Hornstra, G. The effect of supplementation with docosahexaenoic and arachidonic acid derived from single cell oils on plasma and erythrocyte fatty acids of pregnant women in the second trimester. Prostaglandins Le PubMed
  25. Helland, I. B., Saugstad, O. D., Smith, L., Saarem, K., Solvoll, K., Ganes, T., and Drevon, C. A. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics 2001;108(5):E82. PubMed
  26. Nestel, P., Shige, H., Pomeroy, S., Cehun, M., Abbey, M., and Raederstorff, D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am.J.Clin.Nutr. 2002;76(2):326-330. PubMed
  27. Woodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Barden, A., Watts, G. F., and Beilin, L. J. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients PubMed
  28. Jensen, C. L., Voigt, R. G., Prager, T. C., Zou, Y. L., Fraley, J. K., Rozelle, J. C., Turcich, M. R., Llorente, A. M., Anderson, R. E., and Heird, W. C. Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed
  29. Theobald, H. E., Goodall, A. H., Sattar, N., Talbot, D. C., Chowienczyk, P. J., and Sanders, T. A. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 2007;137(4):973-978.
  30. Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008;18(9):639-645. PubMed
  31. Birch EE, Carlson SE, Hoffman DR, et al. The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexa
  32. Carlson SE, Colombo J, Gajewski BJ, Gustafson KM, Mundy D, Yeast J, Georgieff MK, Markley LA, Kerling EH, Shaddy DJ. DHA supplementation and pregnancy outcomes. Am J Clin Nutr. 2013 Apr;97(4):808-15. PubMed
  33. Escamilla-Nuñez MC, Barraza-Villarreal A, Hernández-Cadena L, Navarro-Olivos E, Sly PD, Romieu I. Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in children. Chest. 2014 Aug;146(2):373-82. PubMed
  34. Fu YQ, Zheng JS, Yang B, Li D. Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. J Epidemiol. 2015;25(4):261-74. PubMed
  35. Imhoff-Kunsch B, Stein AD, Villalpando S, Martorell R, Ramakrishnan U. Docosahexaenoic acid supplementation from mid-pregnancy to parturition influenced breast milk fatty acid concentrations at 1 month postpartum in Mexican women. J Nutr. 2011 Feb;141(2): PubMed
  36. Judge MP, Cong X, Harel O, Courville AB, Lammi-Keefe CJ. Maternal consumption of a DHA-containing functional food benefits infant sleep patterning: an early neurodevelopmental measure. Early Hum Dev. 2012 Jul;88(7):531-7. PubMed
  37. Mulder KA, King DJ, Innis SM. Omega-3 fatty acid deficiency in infants before birth identified using a randomized trial of maternal DHA supplementation in pregnancy. PLoS One. 2014 Jan 10;9(1):e83764. PubMed
  38. Richardson AJ, Burton JR, Sewell RP, Spreckelsen TF, Montgomery P. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study). PLoS One. 2012;7(9):e43909. PubMed
  39. Drugs in Pregnancy and Lactation 2012;25(4);3-4
  40. FDA announces qualified health claims for omega-3 fatty acids. Available at: https://www.fda.gov/Food/LabelingNutrition/ucm072756.htm. Accessed April 15 2019.
  41. Breastfeeding and the use of human milk. Section on Breastfeeding. Pediatrics. 2012;129(3):e827-41. PubMed
  42. Zhang Z, Fulgoni VL, Kris-Etherton PM, Mitmesser SH. Dietary Intakes of EPA and DHA Omega-3 Fatty Acids among US Childbearing-Age and Pregnant Women: An Analysis of NHANES 2001-2014. Nutrients. 2018;10(4). PubMed
  43. Montgomery P, Spreckelsen TF, Burton A, Burton JR, Richardson AJ. Docosahexaenoic acid for reading, working memory and behavior in UK children aged 7-9: A randomized controlled trial for replication (the DOLAB II study). PLoS One. 2018;13(2):e0192909. PubMed
  44. Marc I, Piedboeuf B, Lacaze-Masmonteil T, et al. Effect of maternal docosahexaenoic acid supplementation on bronchopulmonary dysplasia-free survival in breastfed preterm infants: A randomized clinical trial. JAMA. 2020;324(2):157-167. PubMed
  45. Fougère H, Bilodeau JF, Lavoie PM, et al. Docosahexaenoic acid-rich algae oil supplementation on breast milk fatty acid profile of mothers who delivered prematurely: a randomized clinical trial. Sci Rep 2021;11(1):21492. PubMed
  46. Garmendia ML, Casanello P, Flores M, Kusanovic JP, Uauy R. The effects of a combined intervention (docosahexaenoic acid supplementation and home-based dietary counseling) on metabolic control in obese and overweight pregnant women: the MIGHT study. Am J O PubMed
  47. Christifano DN, Gustafson KM, Carlson SE, et al. Maternal docosahexaenoic acid exposure needed to achieve maternal-newborn EQ. Nutrients 2022;14(16):3300. PubMed
  48. Vizzari G, Morniroli D, Alessandretti F, et al. Comparative analysis of docosahexaenoic acid (DHA) content in mother's milk of term and preterm mothers. Nutrients 2022;14(21):4595. PubMed
  49. Yang Y, Li G, Li F, et al. Impact of DHA from algal oil on the breast milk DHA levels of lactating women: A randomized controlled trial in China. Nutrients 2022;14(16):3410. PubMed

See these in context on the Docosahexaenoic Acid (dha) monograph →

Astaxanthin 3 references
  1. Kupcinskas L, Lafolie P, Lignell A, et al. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled
  2. Kistler, A., Liechti, H., Pichard, L., Wolz, E., Oesterhelt, G., Hayes, A., and Maurel, P. Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch.Toxicol. 2002;75(11-12):665-675. PubMed
  3. Choi HD, Youn YK, Shin WG. Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects. Plant Foods Hum Nutr. 2011;66:363-369. PubMed

See these in context on the Astaxanthin monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring